Carlsmed announced a 58% year-over-year revenue increase to $16.1 million in Q1 2026, driven by strong sales of its AI-enabled personalized spine surgery products. The company highlighted clinical data showing a 74% reduction in revision surgeries with its aprevo® implants, supporting its market differentiation. Carlsmed also launched new products including the corra™ cervical plating system and expanded its lumbar platform. It raised its full-year 2026 revenue guidance to $72-$77 million, expecting continued growth and innovation.
Tuya Inc. reported Q2 2026 earnings per share of $0.03 and revenue of $92.90 million, surpassing analyst estimates of $87.83 million. The company achieved 16% year-over-year revenue growth, accelerating from 8.3% in Q1, driven by a 16.9% increase in ...
Barclays raised its price target for Zscaler from $170 to $192, indicating a potential 9% upside from the current price of $176.06. The company enjoys strong analyst support, with 34 out of 45 firms rating it as a Strong Buy, reflecting confidence in...
Aftermath Silver Ltd is progressing drilling at its Berenguela silver-copper-manganese project in Peru and Challacollo silver-gold project in Chile. At Berenguela, the company has completed over 4,000 metres of drilling targeting new areas and upgrad...
Moss Genomics was added to the British Columbia Securities Commission's Issuers in Default list due to non-compliance in its MD&A filing for the period ending March 31, 2026. The company plans to amend and restate its MD&A and interim financial state...
Alphabet continues to be a recommended buy despite recent underperformance, driven by strong revenue, profit, and cash flow growth. Its Google Cloud segment nearly doubled its revenue year-over-year, with profit margins increasing significantly from ...
